AU2015348301B2 - Intranasal administration - Google Patents

Intranasal administration Download PDF

Info

Publication number
AU2015348301B2
AU2015348301B2 AU2015348301A AU2015348301A AU2015348301B2 AU 2015348301 B2 AU2015348301 B2 AU 2015348301B2 AU 2015348301 A AU2015348301 A AU 2015348301A AU 2015348301 A AU2015348301 A AU 2015348301A AU 2015348301 B2 AU2015348301 B2 AU 2015348301B2
Authority
AU
Australia
Prior art keywords
nosepiece
length
oxytocin
nasal
projection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015348301A
Other languages
English (en)
Other versions
AU2015348301A1 (en
Inventor
Per Gisle Djupesland
Colin David Sheldrake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Optinose Inc
Original Assignee
Optinose Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optinose Inc filed Critical Optinose Inc
Publication of AU2015348301A1 publication Critical patent/AU2015348301A1/en
Application granted granted Critical
Publication of AU2015348301B2 publication Critical patent/AU2015348301B2/en
Assigned to Optinose, Inc. reassignment Optinose, Inc. Request for Assignment Assignors: OPTINOSE AS
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0098—Activated by exhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00—Dilators with or without means for introducing media, e.g. remedies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015348301A 2014-11-19 2015-11-19 Intranasal administration Active AU2015348301B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081742P 2014-11-19 2014-11-19
US62/081,742 2014-11-19
PCT/EP2015/077166 WO2016079271A1 (en) 2014-11-19 2015-11-19 Intranasal administration

Publications (2)

Publication Number Publication Date
AU2015348301A1 AU2015348301A1 (en) 2017-05-25
AU2015348301B2 true AU2015348301B2 (en) 2020-09-03

Family

ID=54695714

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015348301A Active AU2015348301B2 (en) 2014-11-19 2015-11-19 Intranasal administration
AU2015348297A Abandoned AU2015348297A1 (en) 2014-11-19 2015-11-19 Intranasal administration

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2015348297A Abandoned AU2015348297A1 (en) 2014-11-19 2015-11-19 Intranasal administration

Country Status (19)

Country Link
US (6) US11052204B2 (enExample)
EP (3) EP3220989B1 (enExample)
JP (2) JP6990583B2 (enExample)
KR (2) KR20170085121A (enExample)
CN (3) CN106999684B (enExample)
AU (2) AU2015348301B2 (enExample)
BR (2) BR112017010561A2 (enExample)
CA (2) CA2966797C (enExample)
DK (2) DK3220989T3 (enExample)
ES (3) ES2949052T3 (enExample)
HK (1) HK1244729A1 (enExample)
IL (2) IL251935A0 (enExample)
MX (2) MX383241B (enExample)
MY (1) MY188242A (enExample)
PL (1) PL3220989T3 (enExample)
RU (2) RU2714168C2 (enExample)
SG (2) SG11201703792XA (enExample)
WO (2) WO2016079267A1 (enExample)
ZA (1) ZA201704149B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311570D0 (en) 2003-05-20 2003-06-25 Optinose As Delivery device and method
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
GB0604444D0 (en) * 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
GB0623731D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery device
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
GB2448193A (en) 2007-04-05 2008-10-08 Optinose As Nasal delivery device
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
JP6243360B2 (ja) 2012-02-24 2017-12-06 オプティノーズ アズ 経鼻配送装置
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
USD761951S1 (en) 2013-05-23 2016-07-19 Optinose As Nosepiece unit
ES2949052T3 (es) 2014-11-19 2023-09-25 Optinose Inc Administración intranasal
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
DK3773834T3 (da) 2018-04-12 2025-05-19 Rocket Science Health Corp Intranasal fluidindgivelsesanordning
KR102148613B1 (ko) * 2019-01-28 2020-10-14 닉스 주식회사 이산화탄소를 이용한 수면 유도시스템
CN110188836B (zh) * 2019-06-21 2021-06-11 西安交通大学 一种基于变分自编码器的脑功能网络分类方法
US20220313895A1 (en) * 2019-08-14 2022-10-06 Gsk Consumer Healthcare Sarl Bi-material nozzle for nasal washes
US11241477B2 (en) 2019-08-29 2022-02-08 New York University Oxytocin compositions for treatment of tinnitus
EP4073214A4 (en) 2019-12-09 2023-12-27 AAK AB (publ) Wax compositions for use in candles and methods of preparing wax compositions
US20220161000A1 (en) * 2020-11-24 2022-05-26 Medtronic, Inc. Multi-durometer attachment device for chronic fixation
CN121288169A (zh) * 2021-04-20 2026-01-09 苏州新劢德医疗器械科技有限公司 一种流体分配设备
CN121550561A (zh) * 2021-04-20 2026-02-24 苏州新劢德医疗器械科技有限公司 流体分配设备
CN114306207A (zh) * 2021-12-30 2022-04-12 电子科技大学 一种以棒棒糖为载体的口腔给药方法
US20230285278A1 (en) * 2022-03-06 2023-09-14 Optinose, Inc. Methods for treating chronic rhinosinusitis
WO2025118074A1 (en) * 2023-12-04 2025-06-12 Rocket Science Health Corp. Olfactory delivery of therapeutic peptides
US20250255745A1 (en) * 2024-02-13 2025-08-14 Breathewave Technologies Inc. Personalized-fit nasal dilator

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09135901A (ja) * 1995-11-15 1997-05-27 Unisia Jecs Corp 鼻腔用投薬器
US20100282246A1 (en) * 2007-04-05 2010-11-11 Optinose As Nasal delivery
US8550073B2 (en) * 2006-03-06 2013-10-08 Optinose As Nasal delivery

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US605436A (en) 1898-06-07 Inhaler
US642748A (en) 1899-02-23 1900-02-06 Arthur Manners Inhaler.
US658436A (en) 1900-05-28 1900-09-25 Hans Hennerich Groth Insufflator.
US746749A (en) 1903-03-18 1903-12-15 George E Seidel Nasal medicator.
US794641A (en) 1905-03-06 1905-07-11 Alfred H Ramey Inhaler.
US902832A (en) 1907-09-20 1908-11-03 Edward F Philbrook Inhaler.
AU693306B2 (en) 1995-01-23 1998-06-25 Direct-Haler A/S An inhaler
US5901703A (en) 1995-02-06 1999-05-11 Unisia Jecs Corporation Medicine administering device for nasal cavities
US5797392C1 (en) 1996-01-22 2001-01-09 Direct Haler As Inhaler
BR9809499A (pt) 1997-05-27 2000-06-20 Direct Haler A S Inalador para medicamentos em pó
GB9719775D0 (en) * 1997-09-18 1997-11-19 Glaxo Group Ltd Device
FR2771296B1 (fr) 1997-11-25 2000-03-10 Sofab Embout nasal avec fermeture d'extremite
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
GB0015309D0 (en) 2000-06-21 2000-08-16 Djupesland Per G Apparatus
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
GB0215270D0 (en) 2002-07-02 2002-08-14 Optinose As Nasal devices
GB0215904D0 (en) 2002-07-09 2002-08-21 Team Holdings Uk Ltd Drug delivery system and method
GB0300008D0 (en) 2003-01-02 2003-02-05 Optinose As Delivery devices
GB2400565B (en) 2003-04-17 2005-03-02 Bespak Plc Nasal drug delivery
GB0311570D0 (en) 2003-05-20 2003-06-25 Optinose As Delivery device and method
GB0319119D0 (en) * 2003-08-14 2003-09-17 Optinose As Delivery devices
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
GB0405477D0 (en) 2004-03-11 2004-04-21 Glaxo Group Ltd A fluid dispensing device
USD530815S1 (en) 2004-03-19 2006-10-24 Optinose As Nasal delivery device
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
JP4765526B2 (ja) 2005-10-04 2011-09-07 オムロンヘルスケア株式会社 吸入器および吸入器用マウスピース
US10478574B2 (en) 2006-01-19 2019-11-19 Optinose As Nasal administration
WO2007093784A1 (en) 2006-02-14 2007-08-23 Optinose As Delivery device and method
GB0602980D0 (en) 2006-02-14 2006-03-29 Optinose As Delivery device and method
GB0604319D0 (en) 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
GB2437488A (en) 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
JP2008062974A (ja) 2006-09-07 2008-03-21 Mitani Valve Co Ltd 内容物放出用容器ならびに、この内容物放出用容器を備えたポンプ式製品およびエアゾール式製品
GB0623731D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery device
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
WO2008122018A1 (en) 2007-04-02 2008-10-09 Abbott Respiratory Llc Breath actuated nasal pump
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
US8342173B2 (en) 2007-07-19 2013-01-01 Silver Eagle Labs Inc. Nasal dilator with cushion layer and variable spring rate
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
CN101980738A (zh) 2008-02-07 2011-02-23 华盛顿大学 圆周气雾设备
EP2242526A4 (en) 2008-02-15 2014-06-18 Timothy Sean Immel AEROSOL TREATMENT DEVICE WITH HIGH FREQUENCY ADMINISTRATION
WO2010029441A2 (en) 2008-09-15 2010-03-18 Optinose As Nasal delivery
GB201015371D0 (en) 2010-09-14 2010-10-27 Optinose As Nasal delivery
GB201020638D0 (en) * 2010-12-06 2011-01-19 Liconsa Laboratorios Sa Inhalator
US9949923B2 (en) * 2011-03-15 2018-04-24 Optinose As Nasal delivery
RU112044U1 (ru) 2011-08-25 2012-01-10 Наиль Минрахманович Нуртдинов Тренажер-ингалятор
JP6243360B2 (ja) 2012-02-24 2017-12-06 オプティノーズ アズ 経鼻配送装置
ES2774159T5 (en) 2012-02-24 2025-09-29 Optinose Inc Nasal delivery devices
PL2817053T3 (pl) 2012-02-24 2019-01-31 Optinose As Urządzenia do podawania donosowego
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
US20160045687A1 (en) 2013-03-26 2016-02-18 Optinose As Nasal administration
USD725769S1 (en) 2013-05-23 2015-03-31 Optinose As Nasal delivery device
USD723156S1 (en) 2013-05-23 2015-02-24 Optinose As Nasal delivery device
USD761951S1 (en) 2013-05-23 2016-07-19 Optinose As Nosepiece unit
ES2949052T3 (es) 2014-11-19 2023-09-25 Optinose Inc Administración intranasal
US20220296825A1 (en) 2018-10-04 2022-09-22 Optinose As Exhalation delivery system for and method of treating sinus disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09135901A (ja) * 1995-11-15 1997-05-27 Unisia Jecs Corp 鼻腔用投薬器
US8550073B2 (en) * 2006-03-06 2013-10-08 Optinose As Nasal delivery
US20100282246A1 (en) * 2007-04-05 2010-11-11 Optinose As Nasal delivery

Also Published As

Publication number Publication date
EP3220989B1 (en) 2020-06-24
PL3220989T3 (pl) 2021-03-22
CN111921046A (zh) 2020-11-13
EP3733235C0 (en) 2023-06-14
IL251936B (en) 2020-07-30
MX2017006268A (es) 2017-08-14
EP3220988A1 (en) 2017-09-27
EP3733235A1 (en) 2020-11-04
CA2966797A1 (en) 2016-05-26
KR20170086599A (ko) 2017-07-26
EP3733235B1 (en) 2023-06-14
CN107106792A (zh) 2017-08-29
JP6990583B2 (ja) 2022-01-12
CA2966802C (en) 2022-11-15
KR20170085121A (ko) 2017-07-21
ES2813442T3 (es) 2021-03-23
MY188242A (en) 2021-11-24
CA2966797C (en) 2023-06-27
ES2906984T3 (es) 2022-04-21
BR112017010561A2 (pt) 2017-12-26
RU2017114950A (ru) 2018-12-19
WO2016079271A1 (en) 2016-05-26
BR112017010522B1 (pt) 2022-08-02
DK3220988T3 (da) 2022-02-14
MX383241B (es) 2025-03-13
SG11201703794TA (en) 2017-06-29
JP6937690B2 (ja) 2021-09-22
JP2017538477A (ja) 2017-12-28
AU2015348301A1 (en) 2017-05-25
US11730904B2 (en) 2023-08-22
EP3220989A1 (en) 2017-09-27
US11707586B2 (en) 2023-07-25
US20160310683A1 (en) 2016-10-27
IL251936A0 (en) 2017-06-29
EP3220988B1 (en) 2022-01-12
US20250114543A1 (en) 2025-04-10
ES2949052T3 (es) 2023-09-25
CN106999684A (zh) 2017-08-01
ZA201704149B (en) 2019-12-18
DK3220989T3 (da) 2020-08-24
JP2017538478A (ja) 2017-12-28
RU2017114951A3 (enExample) 2019-04-16
SG11201703792XA (en) 2017-06-29
IL251935A0 (en) 2017-06-29
AU2015348297A1 (en) 2017-05-25
WO2016079267A1 (en) 2016-05-26
US20210275761A1 (en) 2021-09-09
US10940277B2 (en) 2021-03-09
US20230372647A1 (en) 2023-11-23
RU2017114951A (ru) 2018-12-19
CN111921046B (zh) 2022-07-22
HK1244729A1 (zh) 2018-08-17
US20160331916A1 (en) 2016-11-17
US20210322690A1 (en) 2021-10-21
RU2714168C2 (ru) 2020-02-12
CA2966802A1 (en) 2016-05-26
CN107106792B (zh) 2020-08-18
BR112017010522A2 (pt) 2017-12-26
US11052204B2 (en) 2021-07-06
CN106999684B (zh) 2021-03-09
HK1244728A1 (en) 2018-08-17
MX2017006265A (es) 2017-08-14

Similar Documents

Publication Publication Date Title
US11707586B2 (en) Intranasal administration
Spengler et al. Kinetics and dose dependency of intranasal oxytocin effects on amygdala reactivity
Quintana et al. Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial
US11013441B2 (en) Methods and kits for diagnosing, assessing or quantitating drug use, drug abuse and narcosis, internuclear ophthalmoplegia, attention deficit hyperactivity disorder (ADHD), chronic traumatic encephalopathy, schizophrenia spectrum disorders and alcohol consumption
Gully et al. Oxytocin reduces noradrenergic-induced opioid-like withdrawal symptoms in individuals on opioid agonist therapy
HK40033122A (en) Intranasal administration
HK1244728B (en) Intranasal administration
Biagianti INVESTIGATING THE NEUROPHYSIOLOGICAL EFFECTS OF OXYTOCIN ADMINISTRATION ON HEALTHY SUBJECTS AND INDIVIDUALS WITH SCHIZOPHRENIA USING MAGNETO-ENCEPHALOGRAPHY IMAGING.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: OPTINOSE, INC.

Free format text: FORMER OWNER(S): OPTINOSE AS